About
Mass cytometry is a hybrid technique combining flow cytometry and mass spectrometry. It uses antibodies conjugated with heavy metals rather than fluorochromes to label cells expressing proteins of interest, followed by time-of-flight (TOF) mass spectrometry for detection. The advantages include significantly enhanced multiplexing that allows for the comprehensive analysis of various tissue microenvironments.
The Single Cell Imaging and Mass Cytometry Analysis Platform (SCIMAP) offers mass cytometry services for analyzing dissociated tissues and blood (Helios) and tissue sections (Imaging Mass Cytometry (IMC) - Hyperion). Dedicated and highly qualified personnel assists with the experimental design, assay development, and data analysis. In addition, SCIMAP provides validated and customizable antibody panels for detecting immune cell lineage and activation status, and other phenotypes, reducing optimization time and costs.
Leadership Team
Scientific Director
Luke McCaffrey, PhD
Platform Manager
Yuhong Wei, PhD
Tags: Tags: Mass Cytometry Core Facility, McGill Goodman Cancer Institute, GCI Fluidigm, CyTOF, Helios, Hyperion, single-cell mass cytometry, imaging mass cytometry, multiplex immunostaining
